Background. In 2011 Escherichia coli O104:H4 caused an outbreak with >800 cases of hemolytic uremic syndrome (HUS) in Germany, including 90 children. Data on the intermediate outcome in children after HUS due to E. coli O104:H4 have been lacking.
The characteristic triad of hemolytic uremic syndrome (HUS) is nonimmune hemolytic anemia, thrombocytopenia, and renal failure [1] . Hemolytic uremic syndrome usually affects children aged <5 years [1] . In the Western world, most cases are attributed to infections with enterohemorrhagic Escherichia coli (EHEC) belonging to the group of Shiga toxin-producing Escherichia coli (STEC), classically serotyped as E. coli O157:H7 [2] . Shiga toxin-producing E. coli HUS must be differentiated from atypical HUS, which is mostly due to inborn errors in the regulation of the alternative pathway of the complement system [3] .
The key component in the pathogenesis of HUS is Shiga toxin (Stx). After oral ingestion and intestinal infection, STEC elaborate Stx1 and/or Stx2, and these toxins then induce systemic proinflammatory and prothrombotic pathways [4] . Approximately 15% of cases are thought to progress from STEC gastroenteritis to HUS. The renal histological picture in HUS is thrombotic microangiopathy. Other organs, especially the brain, can also be affected, leading to major neurological symptoms such as impaired consciousness and seizures [2] .
Beside sporadic STEC infections, outbreaks may also occur. The largest outbreak reported so far occurred in Germany in 2011 with approximately 3800 cases, including >800 HUS patients [5] . The causative strain was an enteroaggregative E. coli (EAEC) with the serotype O104:H4 that gained the ability to produce Stx2 [6] . Most of the affected patients were adults (88%) with a predominance of women in the case of both STEC gastroenteritis (58%) and HUS (68%) [5] . However, epidemiological data indicate there was no specific susceptibility to HUS among females during this outbreak [7] .
In contrast with children, many adult patients were treated during the outbreak with plasmapheresis, the anti-complement C5-antibody eculizumab, and subsequently with antibiotics. Retrospective analysis of the nonrandomized and noncontrolled data in adults did not show a beneficial effect of this treatment with plasmapheresis and eculizumab [8] [9] [10] .
Spinale et al recently reviewed the data on long-term outcome after HUS in children, with an overall prevalence of sequelae of 20%-40% after HUS. Although most patients showed full recovery of kidney function after HUS, chronic kidney disease (CKD) or end-stage renal disease (ESRD) occurred in 9%-18% and approximately 3% of the patients, respectively. Proteinuria (in 15%-30%) and hypertension (in 5%-15%) are frequently detected in patients after HUS, which might indicate a higher risk of renal or cardiovascular disease later in life [11] .
We previously reported clinical data on the acute phase of 90 children with HUS affected during the 2011 outbreak and a more specific neurological outcome report after 6 months of follow-up in 50 of the patients [12, 13] . At initial short-term follow-up after a median of 4 months, 4 of 90 patients (4.4%) had CKD (n = 3 CKD stage 3-4, and n = 1 CKD stage 5), and neurological symptoms were present in 4 of 90 patients in total (n = 4/23 with major neurological symptoms during HUS) [12] .
Here we present intermediate follow-up data and prognostic risk factors on 72 of these patients with respect to renal and neurological symptoms.
MATERIAL AND METHODS

Patients
Data from medical records of patients who had been included in the German Pediatric HUS Registry during the 2011 outbreak were gathered via an online database and analyzed retrospectively. The initial inclusion criteria have been published in detail elsewhere [12] . Hemolytic uremic syndrome was defined as hemolytic anemia (hemoglobin < 10 g/dL), thrombocytopenia (thrombocytes < 150 × 10 9 /L), and acute renal impairment (creatinine above the age-dependent normal range). Initial neurological symptoms associated with HUS were categorized as impairment of consciousness (stupor or coma), epileptic seizures, focal neurological deficits (eg, hemiparesis), and visual disturbances (double or blurry vision).
The local ethical committees approved the study, and informed consent was obtained from the patients, parents, and/ or guardians.
Renal Outcome
The estimated glomerular filtration rate (eGFR) was calculated by using the appropriate Schwartz formula [14, 15] . Chronic kidney disease was categorized according to the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF-KDOQI) guidelines into stages 1-5 [16] . Proteinuria was defined as albumin/creatinine ratio >0.02 g/g, protein/creatinine ratio >0.2 g/g, ≥100 mg/dL of protein in a dipstick test in a spot urine, or > 0.1 g/m 2 per day of protein in a 24-hour urinecollection if there was proteinuria in 1 spot urine test. Renal sequelae were defined as CKD stage ≥ 2, proteinuria, and/or hypertension at most recent follow-up.
Hypertension
Hypertension was evaluated by casual blood pressure measurements (n = 54) and ambulatory blood pressure monitoring over 24 hours (n = 18). Systolic or diastolic values greater than the corresponding 95th percentile for sex and age were considered hypertensive [17, 18] .
Neurological Outcome
Major symptoms such as focal neurological deficits, epilepsy, and complex neurological syndromes were evaluated during follow-up.
Statistics
Data were analyzed using PRISM (version 6, GraphPad) or STATA (release 14, StataCorp). Descriptive statistics are presented for continuous variables (median and ranges) and for categorical variables (patient counts and percentages). Continuous variables were compared using the Mann-Whitney U test. Pearson's χ 2 test and Fisher´s exact test were used for categorical data, as appropriate. For multivariate analysis logistic regression was used. P < .05 was considered statistically significant.
RESULTS
In total, 72 patients were evaluated after a median follow-up of 3.0 years, including 1 patient after kidney transplantation. One patient of the original cohort of 90 patients died during the acute phase. Of the 89 survivors, 72 patients (81%) were included in the follow-up study. Epidemiological data of the patients are shown in Figure 1A . Fifty-five of the 72 (76%) patients underwent dialysis in the acute phase. Nineteen of 23 (83%) of those who initially had neurological symptoms were included. Seventeen patients, of whom 6 had reached the age of 18, did not return for follow-up investigations. Of these 6, 2 patients received dialysis during the acute disease, and only 1 had neurological symptoms.
Renal Outcome
Data on median eGFR and patients with proteinuria, hypertension, and CKD stages 2-5 at intermediate follow-up are shown in Figure 1 . Eight patients were treated with an angiotensin converting enzyme (ACE) inhibitor; 3 of these did not have any proteinuria or hypertension. The follow-up period in patients with hypertension and without hypertension did not differ (median = 2.8, range = 0.9-4.7 years vs median = 3.0, range = 1.0-4.3 years; P = .95; 5 patients with ACE inhibitor treatment and without hypertension where excluded from the analysis). Accordingly, the follow-up period in patients with proteinuria and without proteinuria did not differ (median = 2.6, range = 1.6-4.1 years vs median = 3.1, range = 1.1-4.7 years; P = .48; 3 patients [1 after kidney transplantation, 2 without data on proteinuria] were excluded from the analysis).
Of the 2 patients with CKD stage 5, 1 patient never recovered renal function, remained on hemodialysis, and received a living-related graft 12 months after STEC-HUS presentation. The other patient could be discontinued from dialysis 7 months after presentation, but renal function worsened again after 19 months, and dialysis had to be reinitiated after 44 months. A total of 32 of 72 (44%) patients had renal sequelae, including 3 of 8 patients with ACE inhibitor treatment without proteinuria or hypertension and 2 patients for whom no data on proteinuria were available (both had hypertension). Neither patients with nor patients without sequelae showed a significant † n = 71; 1 patient after kidney transplantation was excluded. ‡ n = 69; 1 patient after kidney transplantation was excluded, for 2 patients no data were available.
§ 1 patient after kidney transplantation, 1 patient on dialysis who underwent kidney transplantation after completing follow-up (see text). Abbreviations: CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate. Figure 2 . Development of estimated glomerular filtration rate in 3 patients with chronic kidney disease at short-term follow-up. Data on the patient who remained on dialysis after the acute phase and who was subsequently transplanted are not shown. The solid black line shows the patient in whom dialysis could be discontinued 199 days (7 months) after presentation but who worsened over time, with reinstitution of dialysis after 44 months, before living-relation transplantation was performed after 45 months. Abbeviation: eGFR, estimated glomerular filtration rate.
P = .12).
In the univariate analysis, the acute-phase parameters of HUS associated with renal sequelae were dialysis (53% of the patients with dialysis had renal sequelae compared with 18% of patients not requiring dialysis; P = .01) (Figure 3) , duration of dialysis (P = .01), duration of oligo-/anuria (P = .05), and hypertension (P = .02) ( Table 1 ). All patients with CKD had been on dialysis for >11 days (1 patient for 42 days; 1 patient for 199 days; 1 patient remained on dialysis). However, multivariate analysis revealed no significant association regarding these parameters.
Neurological Outcome
At most recent examination, 1 patient (1.4%) had ongoing severe neurological symptoms with dystonia, dysphagia, and dysarthria. This patient received deep-brain stimulation.
Another patient recovered completely during follow-up. However, this patient had a mild hemiparesis for 1.25 years after HUS, and 10 months after HUS developed a probably symptomatic focal epilepsy, which was treated for 1.75 years with antiepileptic drugs. The antiepileptic therapy was subsequently withdrawn, and the patient had no further seizures. (In previous publications, this patient was described with fine-motor disturbances during short-term follow-up and mild, still-improving hemiparesis during a specific neurological 6-month follow-up [12, 13] .) A third patient was treated prophylactically with an antiepileptic drug due to a pathological electroencephalogram. Because these last two patients did not show overt symptoms according to our definition, they were counted as unaffected.
Outcome After Treatment With Eculizumab
Eculizumab was given to patients during the outbreak for various reasons. Indications were HUS, neurological symptoms, and prolonged dialysis with slow recovery of kidney function. Intermediate follow-up data on 11 of 13 patients (n = 11/12 survivors) treated with eculizumab were available. Six of these 11 patients were also treated with plasmapheresis. Patients (these data were available for 8 of the 11) received eculizumab after a median of 22 (range = 2-115) days after diagnosis of HUS. Another 7 patients received plasmapheresis during the acute phase. Two patients received protein C infusions. In total, 13 patients were treated with plasmapheresis. This treatment was started 2 (range = 0-9) days after diagnosis of HUS in 11 of 13 patients for whom these data were available.
Serum creatinine in patients treated with eculizumab (n = 9; 2 patients were excluded: the patient after kidney transplantation and the patient on dialysis) versus patients not treated (n = 61) did not show a difference at follow-up (mdian = 0.70, range = 0.36-1.67 mg/dL vs median = 0.66, range = 0.26-1.18 mg/dL; P = .53). Three of the 10 (30%; the patient after transplantation was excluded) patients treated with eculizumab versus 16 of the 59 (27%; no data were available in two patients) patients not treated with eculizumab had proteinuria. Hypertension occurred in 4 of 11 (36%) patients treated with eculizumab versus 10 of 61 (16%) patients not treated with eculizumab. Therapy with plasmapheresis and/or eculizumab was not associated with renal sequelae (CKD stage ≥ 2, proteinuria, and/or hypertension) (data not shown).
DISCUSSION
Although STEC-HUS can lead to intermediate and long-term renal sequelae, such as proteinuria, hypertension, and most notably CKD, including ESRD [11, 19] , our current analysis indicates a favorable outcome after the E. coli O104:H4 outbreak in 2011.
Two patients developed ESRD requiring transplantation, which is in line with outcome data from previous case series of other E. coli strains. The majority of patients (n = 54/72; 75%) only received supportive treatment, and the use of eculizumab and/or plasmapheresis had no measurable impact on outcome or complications.
In a recent analysis of pediatric patients from Germany, Switzerland, and Austria, 7% of 274 patients had a reduced glomerular filtration rate (GFR; < 80 mL/min/1.73 m 2 ) after a follow-up of 5 years [19] . In our series, the outcome regarding CKD was similar, with CKD ≥ 2 in 4% of the patients. However, rates of CKD up to 9%-18% and greater after HUS have been described [11] . As in our patients, it has been previously observed that the GFR can improve or deteriorate over time after HUS [20, 21] . Similar to the results of Rosales et al and our results, 2 of 45 (4%) adult patients from the 2011 outbreak from a single center had increased creatinine after 1 year of follow-up [22] . However, decreased eGFR < 90 mL/min calculated from cystatin C was found in Figure 3 . Outcome of patients after dialysis during the acute phase of hemolytic uremic syndrome. † The patient after kidney transplantation was excluded; for 1 patient no data were available; ‡ For 1 patient, no data were available; § χ 2 test. Abbreviation: CKD, chronic kidney disease.
47% of the patients in this study. This was associated with older age (mean age 60 years [eGFR < 90 mL/min] vs 43 years [eGFR > 90 mL/min]) [22] .
Previous reports described proteinuria in around 10%-40% of the cases at long-term follow-up [19, 21, [23] [24] [25] [26] [27] . In the 274 prospectively followed children, 18% had proteinuria 5 years after HUS [19] . Our analysis showed proteinuria in 28% of the examined patients, which corresponds to the previous reports. Substantial variation between the different studies might also be due to the different definitions of proteinuria applied. Again adults affected during the outbreak showed similar results, with albuminuria in 27% of the cases at 1-year follow-up [22] . Although proteinuria in patients after HUS is more common compared with the normal population and proteinuria is associated with impaired kidney function, it is not necessarily a measure for poor outcome. Its predictive value in the long-term perspective for children affected by HUS is unknown [11, 28] .
In our series, 19% of patients presented with hypertension. In previous pediatric case series, the prevalence of hypertension ranged from approximately 5%-15% of the patients after acute HUS [11, 19, 23, 24] . Twenty-five percent of the affected adults in the 2011 outbreak developed de novo hypertension 1 year after the acute illness [22] . It is of note that blood pressure was evaluated by casual measurements in most of the patients in our study. Thus the level of blood pressure could either have been overestimated due to white-coat hypertension or underestimated, and a masked elevated blood pressure might only be detected by ambulatory blood-pressure monitoring [29] . Because the median age of our patients (11.5 years) was unusually high during the outbreak, many patients were already teenagers during follow-up [12] . Screening of cohorts in this age group might reveal up to 15% with elevated blood pressure [29] .
As in other studies, renal long-term sequelae in our cohort were associated with a need for dialysis and the duration of both dialysis and oligo-/anuria during the acute illness [11, 25, 30] . Data from other reports suggest that especially anuria lasting for >10 days predicts poor long-term outcome [11] .
Approximately a quarter of patients have major neurological symptoms during HUS [12] . Due to the fairly good prognosis, data on long-term neurological follow-up are rare. Rosales et al reported neurological sequelae in 4% of the patients [19] . In our cohort, only 1 patient had persistent neurological symptoms at follow-up. However, additional detailed neuropsychological and neuromotor performance tests might reveal further impairment after HUS [13, 31, 32] . A neuropsychological analysis of adults affected during the 2011 outbreak did not show significant deficits 1 year after STEC infection [33] .
Indications for eculizumab and its time of initiation varied substantially among patients. Furthermore, eculizumab was only given to the sickest patients, who also received other treatments, including plasmapheresis. Thus the analysis regarding the effects of this treatment on the long-term outcome of the patients must be treated with caution. The data in adult patients indicate that eculizumab did not have a beneficial effect during the acute phase and on midterm outcome [8, 9, 22] . Additionally, Harambat et al did not find a positive effect of eculizumab treatment in children with STEC-HUS [34] . Early eculizumab treatment of HUS patients with seizures might improve neurologic outcome [35] . However, randomized controlled trials are lacking, and the role of the complement system in the pathogenesis of STEC-HUS is a matter of debate [36] .
Rosales et al reported that plasmapheresis was associated with poorer long-term outcome [19] . As in our study, only the most severely affected patients received plasmapheresis, and neither plasmapheresis nor eculizumab was associated with renal sequelae in our study.
Our study has several limitations because it is retrospective and has a small sample size with an incomplete follow-up of the initial cohort. Overall, renal sequelae were present in 44% of our patients. However, the majority (91%) of these patients had minor complications like proteinuria and/or hypertension without CKD. The relatively high rate of sequelae might also be due to the rather broad and possibly soft definitions of factors contributing to our compound end-point findings. Additionally the rate of patients included in the follow-up who received dialysis in the acute phase (76%) was higher compared with the rate of 71% in 90 patients during the 2011 outbreak, and all patients with CKD were included in the follow-up [12] . Thus, sequelae might be slightly over-reported. Due to its uncontrolled administration, the data for patients treated with eculizumab in particular do not allow specific conclusions about the effect of the treatment. Our data show that sequelae after HUS due to E. coli O104:H4 are equivalent to previous case series of STEC-HUS. It is still unclear which epidemiological, host, and/or E. coli O104:H4 pathogenicity factors were most important for the outbreak in 2011. The course of the disease and the intermediate outcome appear to be comparable with HUS due to other STEC strains [12] . The fact that outcome of HUS is not associated with a given serotype was also shown for the serotypes most often isolated in HUS patients, the so-called "big five" (O157, O26, O111, O103, O145) [19] .
In conclusion, pediatric patients affected during the 2011 outbreak due to E. coli O104:H4 had a favorable intermediate outcome, which is equivalent to previous studies, although a small fraction may progress to CKD stage 5. All patients should undergo yearly follow-up visits after the acute illness, but especially those who were on dialysis and have proteinuria and/or hypertension on follow-up visits.
